Cardiotonics are medications used to strengthen the force of myocardial contraction, thereby improving cardiac output in women with underlying heart failure. During pregnancy, blood volume increases significantly by up to fifty percent, placing an immense workload on a compromised maternal heart. Digoxin remains the primary cardiotonic agent utilized in obstetric practice when heart failure or certain supraventricular arrhythmias complicate gestation. It works by inhibiting the sodium-potassium ATPase pump in cardiac myocytes, leading to an intracellular accumulation of calcium ions that enhances contractility.
Midwives caring for women on cardiotonic therapy must remain vigilant for signs of digitalis toxicity, which include persistent nausea, vomiting, visual disturbances like seeing yellow halos, and dangerous cardiac arrhythmias. Serum digoxin levels require routine monitoring because altered renal clearance and expanded plasma volumes during pregnancy change drug distribution unpredictably.
Normal pregnancy is a hypercoagulable state designed to protect the mother from massive hemorrhage during delivery. This adaptive mechanism involves an increase in clotting factors, notably factors VII, VIII, X, and fibrinogen, alongside a decrease in natural anticoagulant proteins and reduced venous stasis caused by the expanding uterus compressing the pelvic vessels.
While this physiological clotting shift prevents postpartum bleeding, it dramatically raises the risk of thromboembolic events such as deep vein thrombosis and pulmonary embolism. Women with mechanical heart valves, a personal history of clotting disorders, or inherited thrombophilias require therapeutic anticoagulation to survive pregnancy. Midwives must identify high-risk women early in antenatal care so specialized medical management can be initiated promptly.
Managing thrombosis in pregnancy is complicated by how different drugs cross the placenta and affect the developing fetus. Molecular weight dictates whether a pharmacological agent reaches fetal circulation.
| Feature | Heparin (UFH / LMWH) | Warfarin |
|---|---|---|
| Placental Crossing | Does not cross the placenta | Crosses the placenta freely |
| Route of Administration | Parenteral (Subcutaneous or Intravenous) | Oral tablet |
| Fetal Safety | Safe for the fetus throughout pregnancy | High risk of birth defects and fetal hemorrhage |
| Monitoring Test | Activated Partial Thromboplastin Time (aPTT) or Anti-Xa | International Normalized Ratio (INR) |
| Primary Indication in Pregnancy | Treatment and prevention of VTE and valve protection | Restricted use; avoided entirely in the first and third trimesters |
Timing anticoagulation around childbirth is a delicate balance between preventing maternal thrombosis and avoiding catastrophic obstetric hemorrhage, particularly spinal hematomas during regional anesthesia. Women receiving therapeutic low molecular weight heparin must hold their injections at least twenty-four hours before induction of labor or elective Cesarean section. Unfractionated heparin infusions are typically stopped four to six hours prior to delivery and can be restarted shortly afterward if hemostasis is secure.
If a pregnant woman goes into spontaneous labor while still fully anticoagulated, regional anesthesia like an epidural is strictly contraindicated due to the extreme risk of spinal cord compression from an epidural hematoma. Midwives must review the labor ward admission chart for the exact timestamp of the last anticoagulant dose on every single booking.
Midwives play a critical frontline role in monitoring pregnant women on anticoagulants and identifying complications early. Routine checks include observing injection sites for excessive bruising or hematoma formation, monitoring for spontaneous gum bleeding, hematuria, or vaginal spotting, and tracking ordered coagulation profiles.
Should severe bleeding occur or emergency surgery become necessary while a patient is on heparin, prompt reversal is required. Protamine sulfate is the specific antidote for heparin, neutralizing its anticoagulant effect within minutes when administered intravenously. For warfarin toxicity or urgent reversal, vitamin K along with fresh frozen plasma or prothrombin complex concentrates is utilized to rapidly restore functional clotting factors.